{"prompt": "['Interferon beta-1a', 'MESTRE-MS Study', 'EMR200136_59', '14. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple', 'sclerosis. N Engl J Med. 1998;338(5):278-85.', '15.', 'Alam J, McAllister A, Scaramucci J, et al. Pharmacokinetics and Pharmacodynamics of', 'interferon beta-la (IFNB-1a) in healthy volunteers after intravenous, subcutaneous or', 'intramuscular administration. Clin Drug Invest. 1997; 14(1):35-43.', '16. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis', 'lesions. Brain. 1997;120 3):393-9.', '17. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to', 'predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059-69.', '18.', 'Rebif solution for injection in cartridges-SPC, Last Updated on eMC 16-Jul-2015.', '19.', 'Acheson ED. Epidemiology of multiple sclerosis. Br Med Bull. 1977;33(1):9-14.', '20. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): A', 'multicenter observational study on adherence to disease-modifying therapies in patients', 'with relapsingremitting multiple sclerosis. Eur J Neurol. 2011;18: 69-77.', '21. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon', 'beta-la in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504.', '22. Panitch H, Goodin DS, Francis G, et al. Randomized, Comparative Study of Interferon', 'beta-la Treatment Regimens in MS: The EVIDENCE Trial. Neurology 2002;59(10): 1496-', '506.', '23. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new', 'formulation of interferon beta-la (Rebif New Formulation) in a Phase IIIb study in patients', 'with relapsing multiple sclerosis: 96-week results. MultScler. 2009;15(2):219-28.', '24. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b:', 'experience during the first three years. IFNB Multiple Sclerosis Study Group, University of', 'British Columbia MS/MRI Analysis Group. Neurology. 1996;47:889-94.', '25. Rudick R, Simonian N, Alam J, et al. Incidence and significance of neutralizing antibodies', 'to interferon beta-la in multiple sclerosis. Neurology.1998;(50):1266-72.', '26. Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic', 'device for self-injection of subcutaneous interferon beta-la in relapsing multiple sclerosis:', 'an international, single-arm, multicentre, Phase IIIb study. BMC Neurol. 2010,', 'Apr 30;10:28.', '27. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. A randomized, multicentre, open-', 'label, parallel-group study of the tolerability of interferon beta-la (Rebif) administered by', 'CONFIDENTIAL', '45/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'auto injection or manual injection in relapsing-remitting multiple sclerosis. MultScler.', '2005;11:585-91.', '28. Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for', 'multiple sclerosis treatment. ActaNeurol Scand. 2006;113:156-62', '29. Gasperini C, Ruggieri S, Mancinelli CR, et al. Advances in the treatment of relapsing-', 'remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag.', '2013;9 73-85.', '30.', 'Filippini G, Del Giovane C, Vacchi L, et al. Comparative efficacy and risk-benefit balance', 'of modulator and suppressant drugs of the immune system in people with multiple sclerosis', '(MS). Cochrane Database Syst Rev. 2013;Jun 6;6:CD008933.', '31. Atkinson MJ, Kumar R, Cappelleri JC et al. Hierarchical construct validity of the treatment', 'satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy', 'consumers. Value Health. 2005; Nov-Dec;8:S9-S24.', '32. Simeoni M, Auquier P, Fernandez O et al.; MusiQoL study group. Validation of the', 'Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008', 'Mar; 14(2) 219-30.', 'CONFIDENTIAL', '46/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}